Single-Use Bioreactors Market By Product Type (Single-Use Bioreactor Systems, Media Bags, Filtration Assemblies, Bioreactor), By Cell Type (Mammalian Cells, Bacterial Cells, Yeast Cells, Insect Cells, Plant Cells, Others), By Type of Molecules (Vaccines, Monoclonal Antibodies {mAbs}, Stem Cells, Recombinant Proteins, Biosimilars), By Application (Biopharmaceutical Manufacturing, Cell and Gene Therapy, Vaccines Production, Monoclonal Antibody Production, Process Development, Research and Development {R&D}, Pilot-scale and cGMP Manufacturing), By End User (Pharmaceutical & Biotechnology Companies, Contract Manufacturing Organizations {CMOs}, Contract Research Organizations {CROs}, Academic & Research Institutes), Global Market Size, Segmental Analysis, Regional Overview, Company Share Analysis, Leading Company Profiles, and Market Forecast, 2025–2035.

---

Industry Outlook

The Single-Use Bioreactors Market accounted for USD 5.01 Billion in 2024 and USD 5.86 Billion in 2025 is expected to reach USD 28.28 Billion by 2035, growing at a CAGR of around 17.04% between 2025 and 2035. The rising demand for biologics, technological advancements, and cost-effectiveness drives the adoption of scalable, efficient single-use bioreactor systems in biomanufacturing. The single-use bioreactors market is the term used to refer to bioreactor systems used for biologics production (such as vaccines, monoclonal antibodies, and recombinant proteins) employing disposable components. These systems are flexible, cost-effective, and scalable in biopharmaceutical manufacturing. The market is supported by the rising demand for biologics, the latest developments in cell and gene therapies, and the expanding introduction of flexible manufacturing systems. Industry trend is positive, with a distinct move towards single-use technologies because of the rapidness of their setup processes, minimal contamination risks, and low capital investment. North America and Europe are still dominant, but Asia-Pacific is a rising high-growth market.

Industry Experts Opinion

"As the demand for biologics continues to grow, single-use bioreactors are pivotal in accelerating production timelines and reducing costs. Our innovations in bioreactor systems and related technologies are shaping the future of biomanufacturing, empowering our clients to achieve greater flexibility and scalability in their operations."

• John B. Danaher, CEO of Danaher Corporation.

Report Scope:

Market Dynamics

Rising demand for biologics fuels the need for scalable, efficient bioreactor systems.

The increased demand for biologics (including vaccines, monoclonal antibodies, and recombinant proteins) has had a great effect on the production of biopharmaceuticals; therefore, the increased demand has led to a need for more flexible and efficient manufacturing systems. Bioreactors are very important in this process, and they allow growing cells that produce biologic drugs. With the increasing size of the global biologics market, the demand for bioreactors that can accommodate large-scale production significantly rises. Single-use bioreactor systems are quite attractive in terms of flexibility, cost-effectiveness, and reduced risk of contamination, making this the most viable system for high-volume biologics manufacturing. These systems provide manufacturers with the opportunity to adapt rapidly to the variability of production demands and regulatory influence.

The increasing amount of personalized medicines and gene therapies that require adaptable production procedures serves as an additional justification for the need for speed and optimization in the manufacturing of biologics. With the continuing dominance of biologics in the healthcare market, the market for bioreactors that can grow production effectively will continue expanding. Single-use bioreactors provide the solution to the increasing demand while keeping a high level of production standards. This tendency is likely to be extended since the biopharmaceutical industry is working toward higher capacities for more efficient generation of life-saving therapies.

Technological advancements in sensors and monitoring systems enhance single-use bioreactor performance.

Advancements in sensors and monitoring systems are transforming the performance of single-use bioreactors for better performance and reliability. These innovations allow for real-time surveillance of key parameters, including pH, level of dissolved oxygen, temperature, and nutrient levels, to favor optimal conditions for cell growth and product formation. Enhanced sensors increase the degree of precision and accuracy of the data collected, resulting in better process control and reproducibility. Automation of the monitoring systems combined with sophisticated control algorithms enables the modification with human interference to be made with ease, hence minimizing human interference and error chances. In addition, such developments promote more robust data integrity, which is instrumental for meeting the strict regulatory requirements of biopharmaceutical production.

The application of smart sensors in single-use bioreactors enables manufacturers to follow the whole production process and increase transparency and traceability. Also, these systems make predictive analytics, which allows us to identify future problems early on, avoiding disruption of the production cycle. Such technological advancements have increased yields and lowered contamination risks, as well as faster turnaround times necessary for responding to the increasing demand for biologic products. As the biomanufacturing industry embraces these innovations, single-use bioreactors become even more essential in massive commercial production.

Limited availability of skilled workforce may slow down the implementation of advanced bioreactor technologies.

The lack of availability of a skilled workforce is one of the key problems disrupting the dissemination of advanced bioreactor technologies among the biopharmaceutical community. With growing demands for complicated biologic products, organizations need well-trained staff to operate, maintain, and optimize sophisticated single-use bioreactors. Nevertheless, the pace of technological change is invariably too fast relative to the supply of available workers who are technically skilled, especially in the case of emerging markets. Such a skills gap may cause inefficiency in biomanufacturing, as companies are unable to use the full potential of their systems of bioreactors. Moreover, training programs and educational materials should be adapted to match these technological developments, which will require considerable investment from both the public and private sectors.

The lack of a qualified labor force can also result in an increased price of labor, which can also affect manufacturers. Consequently, companies may experience delays in scaling production and adopting new biomanufacturing capabilities. This workforce shortage must be addressed to guarantee a seamless incorporation and effective use of advanced bioreactor technologies. Collaborations with academic bodies, support from the government for training purposes, and investments in automation technologies could close the gap. The market for biologic products might outpace the ability of the biopharmaceutical industry to produce them if it lacks a robust workforce with a high degree of skill.

Increasing demand for personalized medicines creates opportunities for scalable and flexible bioreactor systems.

The growing demand for personalized medicines is providing lucrative opportunities for scalable and flexible bioreactor systems in the biopharmaceutical industry. Diagnosis-oriented treatment, or ‘personalized medicine,’ may demand very flexible processes of production given the small batch sizes and different types of therapies involved. Single-use bioreactors, which scale both effectively and flexibly, are perfect for such a role, where manufacturers can manufacture biologics affordably and convincingly. These systems can be easily adapted for other types of therapies, such as gene, monoclonal antibody, or cell therapies, which are critical to personalized medicine. With the trend toward personalized treatments rising, there is a need for bioreactors to accommodate various production needs to increase.

The single-use bioreactors’ versatility enables a fast turnaround to deviating market conditions, thereby accelerating the time-to-market of new therapies. This move towards personalized medicine creates new business opportunities for bioreactor manufacturers and innovation to come up with customized solutions to address the increasing precision treatment demand. In an era of increased interest in personalized therapeutic solutions, the supply of bioreactor systems should be set to rise drastically.

Expansion of cell and gene therapies creates new applications for advanced bioreactor technologies.

The growing field of cell and gene therapy is opening up new application markets for advanced bioreactor technologies, opening up exciting growth possibilities in biomanufacturing. Cell and gene therapies that involve the alteration or replacement of defective genes or cells that are needed in healing diseases require very highly specialized and scalable production systems. These therapies tend to be manufactured in smaller quantities and require complicated procedures, making it a prerequisite to have the capacity to deploy bioreactors with the ability to accommodate divergent cell types and genotypical material and produce high-quality material. Advanced bioreactor technology, such as single-use and modular options, is best suited for these applications because of its flexibility and scalability with a lower risk of contamination.

As the need for personalized cell and gene therapies grows, bioreactors will become critical in terms of making a faster, more efficient production process possible. Moreover, advances in bioreactor systems, including automated monitoring, in-situ real-time analytics, and process control, allow for their improved effectiveness for these complex therapies. As gene-editing equipment, including CRISPR and cell-based therapies, continues to advance, there is a great need for bioreactor solutions to be able to support these innovations. This opens a broadening market for bioreactor manufacturers to create custom technologies that support the specific needs of the cell and gene therapy environment.

Segment Analysis

Based on the product type, the Single-Use Bioreactors Market is classified into single-use bioreactor systems, media bags, filtration assemblies, and bioreactor accessories. Single-use bioreactor systems, such as stirred tank, wave-induced motion, and bubble column reactor systems, dominate the market because of their scalability and utility in biologics. These media bags are central to nutrition under market and waste clearance for market growth. Since filtration assemblies are critical to achieving product purity and sterility for optimal bioprocessing, they are considered a critical component. Additionally, rodents, tubing, connectors, sensors, and sampling systems of bioreactors make bioreactors more functional and easier to operate. As the demand for biologics increases, so does the market for media bags and filtration assemblies. The change toward disposable components in biomanufacturing is consistent with the fast growth in demand for all the product segments cited above.

Based on the application, the Single-Use Bioreactors Market is classified into biopharmaceutical manufacturing, cell and gene therapy, vaccine production, monoclonal antibody production, process development, research and development, and pilot-scale manufacturing. The largest segment, biopharmaceutical manufacturing, is fueled by the growing requirements of biologics such as monoclonal antibodies and recombinant proteins. The application growing fastest is cell and gene therapy, due to progress in personalized medicine and regenerative therapy. Vaccine production also adopts single-use bioreactors massively because of speed and scalability. Process development and R&D use these bioreactors to optimize biomanufacturing processes. Besides, pilot-scale manufacturing is increasingly being used as firms strive to find flexible production strategies and cost-efficient production strategies for clinical trials. These are all applications that enjoy this efficiency, options of contamination control, and economy facilitated by single-use bioreactor technology.

Regional Analysis

The North American Single-Use Bioreactors Market is growing due to the strong presence of established biopharmaceutical firms, contract manufacturers, and research institutes in the region. If we consider the country of its origin, then the U.S. is playing an important role, having a developed health care infrastructure and continuous innovation of biologics, vaccines, and gene therapies. The area enjoys high adoption of state-of-the-art technologies and government initiatives to encourage the development of biopharma, as well as numerous clinical trials. Moreover, growth in personalized medicine and regulatory support for expediting the approval ensures faster growth in the market. The developed manufacturing capabilities and strong demand for biologics in North America will fuel the growth of the market in the next few years. The region’s high level of investment in biotechnology guarantees its dominance in the world market.

The Asia-Pacific Single-Use Bioreactors Market is the fastest growing, due to the rapid development of biotechnology and the emergence of solutions for affordable healthcare. Countries such as China, India, and Japan are experiencing tremendous growth because of the increasing level of investments in the biopharmaceutical and biotechnology sectors on the one hand and attractive government policies and initiatives to promote local manufacturing on the other. The proliferation of CMOs and the increasing use of single-use technologies for biomanufacturing are major drivers. Moreover, the large population and rising prevalence of chronic diseases in the region create an increasing demand for biologics. The growth of the market is being accelerated by international collaborations that Asia’s new biopharma hubs are drawing. With improved manufacturing capabilities and infrastructure, the area stands to experience further growth in the global market.

Competitive Landscape

The competitive environment of the Single-Use Bioreactors Market is extremely dynamic, with major players including Thermo Fisher Scientific, Sartorius, Merck KGaA (MilliporeSigma), Danaher Corporation (Cytiva), and Eppendorf, who dominate the Single-Use Bioreactors Market. These are companies that thrive by providing a wide variety of products, which involve bioreactor systems, media bags, filtration assemblies, and accessories as well. There is competition intensifying as the firms work to expand their product mandates, increase efficiency in operations, and create innovative solutions that will work for the cell and gene therapy applications.

Partnerships, acquisitions, and collaborations are common ways of deepening market position and getting an advantage over rivals. There are also smaller actors, such as PBS Biotech and Applikon Biotechnology, who are finding a niche with specific types of bioreactor systems and providing a cost-effective alternative. Big technological strides are being made in the market, such as automation and real-time monitoring, meant to enhance bioprocessing. Compliance with regulation, quality of the product, and any form of customer support are still value additions to a competitive edge. With the increasing demand for biologics and personalized medicines, competition will continue to grow, which will force companies to continue innovating with their products.

Single-Use Bioreactors Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Free Sample Report

Recent Developments:

• In October 2024, Technological advancements in single-use bioreactors are enhancing process control, data integrity, and reproducibility, with innovations in disposable sensors and monitoring systems.
• In March 2024, the shift towards larger-capacity bioreactors is evident, with bioreactors exceeding 1,500 liters capturing a significant share of the market, driven by the demand for high-volume biologics production.

Report Coverage:

By Product Type

• Single-Use Bioreactor Systems
• Media Bags
• Filtration Assemblies
• Bioreactor Accessories

By Cell Type

• Mammalian Cells
• Bacterial Cells
• Yeast Cells
• Insect Cells
• Plant Cells
• Others

By Type of Molecules

• Vaccines
• Monoclonal Antibodies (mAbs)
• Stem Cells
• Recombinant Proteins
• Biosimilars

By Application

• Biopharmaceutical Manufacturing
• Cell and Gene Therapy
• Vaccines Production
• Monoclonal Antibody Production
• Process Development
• Research and Development (R&D)
• Pilot-scale and cGMP Manufacturing

By End User

• Pharmaceutical & Biotechnology Companies
• Contract Manufacturing Organizations (CMOs)
• Contract Research Organizations (CROs)
• Academic & Research Institutes

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of Middle East & Africa

List of Companies:

• Thermo Fisher Scientific Inc.
• Sartorius AG
• Danaher Corporation
• Merck KGaA
• Eppendorf SE
• PBS Biotech, Inc.
• Applikon Biotechnology B.V.
• Pall Corporation
• Cellexus Ltd.
• Distek, Inc.
• Pierre Guérin Technologies
• Able Biott Corporation
• Meissner Filtration Products, Inc.
• Celltainer Biotech B.V.
• CerCell ApS

Frequently Asked Questions (FAQs)